ArticleCritical care explorations2026
The Association of Iatrogenic Withdrawal With Opioid and Benzodiazepine Weaning in Children With Bronchiolitis: A Single-Center, Retrospective Cohort Study, 2012-2022.
Article in Critical care explorations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to determine the decrease in opioid and benzodiazepine doses associated with the development of withdrawal in children.
settingElectronic health record data.
interventionNone. PATIENTS: Four hundred and seven children who received invasive mechanical ventilation (IMV) between January 1, 2012 and January 1, 2022 with Withdrawal Assessment Tool-1 (WAT-1) scores during their IV opioid wean were included. MEASUREMENTS AND MAIN
resultsThe primary outcome was development of withdrawal, defined as a WAT-1 score greater than or equal to 3, during the IV opioid weaning phase. Descriptive data included age, weight, insurance, race, ethnicity, language, comorbidities, length of stay, and IMV duration. WAT-1 scores were recorded, and the cumulative IV and enteral opioids, benzodiazepines, and A2As were calculated. Recent changes in IV opioid and benzodiazepine doses were assessed in the 16 hours before each WAT-1 score divided into 4-hour periods. Doses were compared across 4-hour periods, and a multivariable mixed-effects model was used to assess their association with withdrawal. The presence of greater than or equal to 2 pediatric complex chronic condition classification system version 2 (CCC-V2) diagnosis categories (odds ratio [OR] 3.35; 95% CI, 2.61-5.15) was associated with withdrawal. Heart disease, prematurity, and IV opioid class switching did not qualify for model inclusion. Cumulative IV opioid dose and a decrease in opioid exposure between 16-12 and 4-0 hours before the WAT-1 score were associated with withdrawal (OR 1.02; 95% CI, 1.01-1.03; OR 1.92; 95% CI, 1.38-3.16). Morphine was associated with increased odds of withdrawal compared with fentanyl and hydromorphone (OR 1.48; 95% CI, 1.37-1.81). The model did not establish an association between cumulative IV benzodiazepine exposure or IV benzodiazepine dose decrease and withdrawal.
conclusionsPatients with a higher cumulative IV opioid dose, an IV opioid wean in the preceding 8-12 hours, and greater than or equal to 2 CCC-V2 categories had the highest odds of withdrawal in this single-center study. Morphine was associated with increased odds of withdrawal as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.